RxDoctor Payments Data

Indranil Debnath, MD

Otolaryngology · Winter Park, FLNPI 1649488735

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Stryker accounts for 61.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $35,901 and has fallen 93.9% since, to $2,172 in 2025. Among otolaryngology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,280in general payments, 2019–2025

Across 253 payments — averaging $431.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$67K
  • Optinose US, Inc.$41K
  • Regeneron Healthcare Solutions, Inc.$516
  • Aerin Medical Inc.$231
  • Acclarent, Inc$222
  • Sanofi$191
  • plus $555 from 11 others

What the payments were for

  • Consulting fees$57,27552%
  • Speaking & faculty fees$34,09531%
  • Travel & lodging$12,15011%
  • Food & beverage$5,6385%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,280 in reported general payments places this provider in the 95th percentile of 586 otolaryngology providers in Florida.

See all otolaryngology providers in Florida

Medicare billing

Part B allowed, 2024
$314,541
Medicare patients
553
Services billed
2,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab36$140,406
XhanceFluticasone Propionate58$41,065
Azelastine Hcl260$8,844
Ipratropium Bromide164$4,575
Fluticasone Propionate127$2,151
Ofloxacin73$1,664
Omeprazole106$1,619
Levocetirizine Dihydrochloride48$921
Famotidine60$877
Fluocinolone Acetonide Oil18$854
Prednisone62$706
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav45$588
Doxycycline Hyclate33$335
Mupirocin48$296
Methylprednisolone47$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$40,571$41,06558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 otolaryngology providers in Florida.

Other otolaryngology in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →